How long should you stay on Mounjaro for weight loss?

No licensed treatment limit is set for tirzepatide in the UK; duration is decided by the prescriber based on your individual response and health picture.
NICE guidance (TA1026) includes a 6-month checkpoint: if less than 5% of body weight is lost at the highest tolerated dose, continuing treatment should be reviewed.
Stopping abruptly can allow appetite and weight to return; any decision to stop or pause should be made with your prescriber, not unilaterally.
Every repeat order at nume is clinically re-reviewed — there are no automatic renewals, so your prescriber stays across your progress throughout.

There is no single fixed duration. Most adults stay on Mounjaro for at least 12 months, and many continue beyond that — how long suits you depends on how your weight responds, whether you meet your health goals, and what your prescriber decides on each clinical review. Mounjaro (tirzepatide) is a prescription-only medicine: a GPhC-registered prescriber, not a timer, decides when treatment continues or stops. This page sets out the factors that shape that decision so you can go into the conversation informed.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What actually decides how long you stay on Mounjaro, and when stopping makes sense

The 6-month checkpoint that NICE built in

UK clinical guidance does not put an expiry date on tirzepatide. What NICE's appraisal of tirzepatide (TA1026) does include is a practical checkpoint: at 6 months on the highest dose you've tolerated, your prescriber should assess whether you've lost at least 5% of your starting body weight. If you haven't, continuing is unlikely to be appropriate and the treatment should be reviewed. This isn't a failure point; it's a built-in safeguard that keeps treatment purposeful rather than indefinite.

Most people who respond well pass that marker comfortably. In the SURMOUNT-1 trial, participants on the 15mg dose lost an average of around 20–21% of body weight over 72 weeks, a figure that puts the 5% threshold well within reach for the majority. But trial populations and real-world patients aren't identical, which is exactly why individual review matters.

If you are responding well, there is no clinical instruction to stop. The prescriber's job at each review is to weigh the ongoing benefit against any side effects, your changing health picture, and your own goals. That conversation can, and often does, lead to treatment continuing beyond a year. You can read more about the broader duration of Mounjaro treatment on a dedicated page.

What happens to weight when Mounjaro stops

This is the practical question most people are really asking. Tirzepatide works while you take it: it slows gastric emptying, signals fullness through two gut-hormone pathways, and reduces appetite. When the medicine leaves your system, those signals quieten. Weight regain is a recognised pattern after stopping any GLP-1 or dual-agonist medicine, and it is not a sign of personal failure, it reflects the underlying biology of weight regulation.

That does not mean everyone regains everything, or that stopping is wrong. Some people reach a stable lower weight with lasting lifestyle changes in place and, with their prescriber's agreement, step down and stop. Others find that appetite returns significantly and that long-term treatment is the right choice for them, in the same way someone might take antihypertensives long term. The question of how long you can stay on Mounjaro covers this in more detail, including what monitoring looks like over time.

The honest answer is that science does not yet have 10-year data on tirzepatide, it is a Black Triangle medicine, meaning the MHRA requires additional monitoring while longer-term evidence accumulates. Prescribers factor that into individual decisions. If you are thinking through your own situation, our page on how long you should be on tirzepatide walks through the key considerations in plain language. The NHS tirzepatide page is a useful starting point for understanding what is and isn't yet known.

The decision your prescriber makes at each review

At nume every repeat is a fresh clinical assessment, not a rubber stamp. A real clinician reads your answers before any medicine is dispensed. The things a prescriber weighs up each time include: how your weight has tracked since the last review, any side effects you've reported, whether your dose still feels appropriate, and whether your broader health has changed. For anyone asking how long they should use Mounjaro for weight loss, this ongoing review is exactly the mechanism that keeps the answer personalised.

Prescribers will also consider practical realities. Cost is one of them, tirzepatide is not cheap, and there is no shame in that factoring into the conversation. The cost of Mounjaro treatment page gives honest context on what private treatment involves. Some patients move to the NHS route once they qualify under the phased rollout; others stay private. Either way, the clinical decision about duration does not change.

One thing worth knowing: the pen that arrives (tracked by DPD, in plain unbranded packaging) contains four weekly doses. That four-week rhythm maps neatly to the review cycle. It is a practical cadence, not an arbitrary one.

Planning ahead: what a good stopping strategy looks like

If you and your prescriber decide the time is right to stop, a gradual plan tends to work better than an abrupt end. That might mean staying at a lower maintenance dose for a period before stopping, intensifying lifestyle support, or simply agreeing a monitoring plan so that any significant regain is caught early. None of that is something to work out alone.

People often ask whether they can restart Mounjaro after stopping. The clinical answer is that suitability would need to be reassessed at the time, in the same way it was the first time. If you're weighing up how long you should take tirzepatide and want a fuller picture before speaking to a prescriber, that page brings together the clinical and practical factors worth knowing. If you're weighing up whether treatment is right for you now, or thinking about how long it might run, the clearest next step is a consultation with a prescriber who can look at your individual picture. Our clinical team, led by our clinical prescriber, does exactly that, same-day review, no waiting list, no automatic anything. Explore your options at our treatment page when you're ready.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions